1. Market Research
  2. > Healthcare Market Trends
  3. > UnitedHealth Group Incorporated - Strategy and SWOT Report

Introduction

UnitedHealth Group Incorporated - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on UnitedHealth Group Incorporated required for business and competitor intelligence needs

- A study of the major internal and external factors affecting UnitedHealth Group Incorporated in the form of a SWOT analysis

- An in-depth view of the business model of UnitedHealth Group Incorporated including a breakdown and examination of key business segments

- Intelligence on UnitedHealth Group Incorporated’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about UnitedHealth Group Incorporated, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

UnitedHealth Group Incorporated (UHG or 'the group') is a diversified health and well-being group. It offers an array of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. The group primarily operates in the US where it is headquartered in Minnetonka, Minnesota, and employed approximately 170,000 people as of December 31, 2014. The group recorded revenues of $130,474 million during the financial year ended December 2014 (FY2014), an increase of 6.5% over FY2013. The operating profit of the group was $10,274 million in FY2014, an increase of 6.8% over FY2013. The net profit of the group was $5,619 million in FY2014, a decrease of 0.1% as compared to FY2013.

Reasons to Purchase:

- Gain understanding of UnitedHealth Group Incorporated and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess UnitedHealth Group Incorporated as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on UnitedHealth Group Incorporated’s business structure, strategy and prospects

Table Of Contents

UnitedHealth Group Incorporated - Strategy and SWOT Report
Company Overview
Business Description
History
Key Employees and Biographies
Company View
Locations and Subsidiaries
SWOT Analysis
Revenue Analysis
Key Competitors
Major Products and Services

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016

  • $ 2000
  • Company report
  • June 2016
  • by Global Markets Direct

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) ...

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015

  • $ 2000
  • Company report
  • December 2015
  • by Global Markets Direct

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) ...

3D Cell Culture Technologies Patent Landscape

3D Cell Culture Technologies Patent Landscape

  • $ 5489
  • Company report
  • September 2016
  • by KnowMade

IP landscape for 3D cell culture technologies offers an important space to big entities as well as for small companies 3D CELL CULTURE : REPRODUCING AN IN VIVO-LIKE ENVIRONMENT IN VITRO The patent landscape ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.